Previous 10 | Next 10 |
Sierra Oncology (NASDAQ: SRRA ): Q4 GAAP EPS of -$0.19 beats by $0.04. More news on: Sierra Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 preliminary data anticipated in H1 2019 - VANCOUVER , Feb. 28, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for th...
- Late-breaking oral presentation to report preclinical mechanistic and efficacy data for immunotherapy combined with SRA737 + LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer models - - Late-breaking abstract reporting preclinical efficacy for Cdc7 inhibito...
- "Addressing Intrinsic & Acquired PARP Inhibitor Resistance Through Chk1 Inhibition" scheduled for 9:00 am ET on January 30 in Boston - VANCOUVER , Jan. 23, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancin...
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib Canada NewsWire VANCOUVER, Dec. 3, 2018 - 44% of transfusion dependent myelofibrosis patients (multi-study aggregate N=152) were trans...
- "Targeted Therapeutics for Hematology & Oncology" scheduled for 5:20 p.m. GMT on November 14, 2018 - VANCOUVER , Nov. 7, 2018 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treat...
Sierra Oncology ( SRRA +5.3% ) is up on light volume following its release of data from a Phase 2 translational study of momelotinib in 41 transfusion-dependent myelofibrosis (MF) patients. The results will be presented at ASH in early December. More news on: Sierra Oncology, Inc., Hea...
Sierra Oncology to Report Clinical Data at ASH 2018 from Translational Biology Study of Momelotinib in Transfusion Dependent Patients Canada NewsWire VANCOUVER, Nov. 1, 2018 – Biomarker data obtained from 41 transfusion dependent patients support ACVR1 mechanism of ac...
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more ...
Sierra Oncology to Host KOL Call with Dr. Srdan Verstovsek Presenting "Unmet Medical Needs in Myelofibrosis" Canada NewsWire VANCOUVER, Oct. 4, 2018 VANCOUVER , Oct. 4, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on...
News, Short Squeeze, Breakout and More Instantly...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...